CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-08-07 | Eansor Norman David SVP - Novus Biologicals | Grant or award · Stock Options (Right to Buy) | +15,948 | 15,948 | ||
| 2019-08-07 | Eansor Norman David SVP - Novus Biologicals | Grant or award · Stock Options (Right to Buy) | +21,265 | 21,265 | ||
| 2019-08-07 | Furlow Brenda S. SVP - General Counsel | Grant or award · Restricted Stock Units | +1,969 | 1,969 | ||
| 2019-08-07 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Options (Right to Buy) | +9,968 | 9,968 | ||
| 2019-08-07 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Options (Right to Buy) | +13,290 | 13,290 | ||
| 2019-08-07 | Hippel James Chief Financial Officer | Grant or award · Restricted Stock Units | +3,938 | 3,938 | ||
| 2019-08-07 | Hippel James Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +19,936 | 19,936 | ||
| 2019-08-07 | Hippel James Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +26,581 | 26,581 | ||
| 2019-08-07 | Kelderman Kim Pres. Diagnostics & Genom | Grant or award · Restricted Stock Units | +2,363 | 2,363 | ||
| 2019-08-07 | Kelderman Kim Pres. Diagnostics & Genom | Grant or award · Stock Options (Right to Buy) | +11,961 | 11,961 | ||
| 2019-08-07 | Kelderman Kim Pres. Diagnostics & Genom | Grant or award · Stock Options (Right to Buy) | +15,948 | 15,948 | ||
| 2019-08-07 | Kummeth Charles R. Chief Executive Officer | Grant or award | +11,291 | 103,467 | ||
| 2019-08-07 | Kummeth Charles R. Chief Executive Officer | Grant or award · Restricted Stock Units | +16,937 | 16,937 | ||
| 2019-08-07 | Kummeth Charles R. Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +85,725 | 85,725 | ||
| 2019-08-07 | Kummeth Charles R. Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +57,150 | 57,150 | ||
| 2019-07-10 | Kummeth Charles R. Chief Executive Officer | Option exercise | +16,969 | $67.46 | $1.1M | 109,145 |
| 2019-07-10 | Kummeth Charles R. Chief Executive Officer | Sale | −6,566 | $212.75 | $1.4M | 102,579 |
| 2019-07-10 | Kummeth Charles R. Chief Executive Officer | Sale | −9,909 | $213.32 | $2.1M | 92,670 |
| 2019-07-10 | Kummeth Charles R. Chief Executive Officer | Sale | −494 | $214.07 | $106K | 92,176 |
| 2019-07-10 | Kummeth Charles R. Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −16,969 | 0 |
Page 51 of 53 · 1,043 trades